SG11201907102XA - Immunological biomarker for predicting clinical effect of cancer immunotherapy - Google Patents
Immunological biomarker for predicting clinical effect of cancer immunotherapyInfo
- Publication number
- SG11201907102XA SG11201907102XA SG11201907102XA SG11201907102XA SG11201907102XA SG 11201907102X A SG11201907102X A SG 11201907102XA SG 11201907102X A SG11201907102X A SG 11201907102XA SG 11201907102X A SG11201907102X A SG 11201907102XA SG 11201907102X A SG11201907102X A SG 11201907102XA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer immunotherapy
- clinical effect
- predicting clinical
- immunological biomarker
- biomarker
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title 1
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 230000007012 clinical effect Effects 0.000 title 1
- 230000001900 immune effect Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
- G01N2333/70564—Selectins, e.g. CD62
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017020685 | 2017-02-07 | ||
JP2017110069 | 2017-06-02 | ||
PCT/JP2018/004090 WO2018147291A1 (en) | 2017-02-07 | 2018-02-06 | Immunological biomarker for predicting clinical effect of cancer immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907102XA true SG11201907102XA (en) | 2019-08-27 |
Family
ID=61527481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907102XA SG11201907102XA (en) | 2017-02-07 | 2018-02-06 | Immunological biomarker for predicting clinical effect of cancer immunotherapy |
Country Status (13)
Country | Link |
---|---|
US (3) | US11293924B2 (en) |
EP (2) | EP3580569B1 (en) |
JP (4) | JP6664684B1 (en) |
KR (2) | KR102617574B1 (en) |
CN (2) | CN110446928B (en) |
AU (1) | AU2018218844B2 (en) |
CA (1) | CA3052027A1 (en) |
IL (1) | IL268524A (en) |
MX (1) | MX2019009386A (en) |
SG (1) | SG11201907102XA (en) |
TW (2) | TWI795386B (en) |
UY (1) | UY37594A (en) |
WO (1) | WO2018147291A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201907102XA (en) | 2017-02-07 | 2019-08-27 | Univ Saitama Medical | Immunological biomarker for predicting clinical effect of cancer immunotherapy |
CA3074751A1 (en) | 2017-09-12 | 2019-03-21 | ImmuneSignatures Pty Ltd | Predicting responses to immunotherapy |
CN113330310A (en) * | 2018-11-09 | 2021-08-31 | 皮埃里亚生物科学有限责任公司 | Methods and compositions for determining tumor microenvironment composition |
TW202035702A (en) * | 2019-02-20 | 2020-10-01 | 學校法人埼玉醫科大學 | Peripheral blood biomarker for evaluating anti-tumor immune effect of radiation therapy |
WO2020171141A1 (en) | 2019-02-20 | 2020-08-27 | 学校法人 埼玉医科大学 | Method and composition for predicting long-term survival in cancer immunotherapy |
EP3953712A1 (en) * | 2019-04-10 | 2022-02-16 | Universität Zürich | A method for determining the likelihood of a patient being responsive to cancer immunotherapy |
JP6796737B1 (en) * | 2020-06-02 | 2020-12-09 | 振武 曽 | Multi-item automatic blood cell counter |
US20240264158A1 (en) * | 2020-09-08 | 2024-08-08 | Saitama Medical University | Biomarker for predicting response to cancer treatment |
CN112114129A (en) * | 2020-09-25 | 2020-12-22 | 苏州大学 | Method for detecting tumor specific T cells |
AU2020469045A1 (en) * | 2020-09-25 | 2023-04-27 | Suzhou Ersheng Biopharmaceutical Co., Ltd | Detection method for tumor-specific t cells |
WO2022215843A1 (en) * | 2021-04-06 | 2022-10-13 | (주)에스엠티바이오 | Method for predicting therapeutic response of cancer patient to anticancer immunotherapy using natural killer cells |
WO2023083924A1 (en) * | 2021-11-10 | 2023-05-19 | Institut Gustave Roussy | Products and uses thereof for predicting the sensitivity of a subject to cancer immunotherapy and for selecting optimized therapy |
CN114354931B (en) * | 2021-12-14 | 2023-03-14 | 南方医科大学南方医院 | Application of splenomegaly in determining curative effect of tumor patient immune checkpoint inhibitor treatment |
US12013816B2 (en) | 2022-01-28 | 2024-06-18 | Seagate Technology Llc | Querying metadata in a storage system |
US12013857B2 (en) | 2022-01-28 | 2024-06-18 | Seagate Technology Llc | Identifying hot items in a distributed storage system |
WO2023230548A1 (en) * | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
WO2024185887A1 (en) * | 2023-03-08 | 2024-09-12 | イミュニティリサーチ株式会社 | System, method, and program for specifying cell population |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
JP2006280307A (en) * | 2005-04-01 | 2006-10-19 | Kyoto Univ | Method for producing controllable t cell |
ATE483470T1 (en) * | 2005-12-21 | 2010-10-15 | Sentoclone Ab | METHOD FOR EXPANSION OF TUMOR-REACTIVE T-LYMPHOCYTES FOR IMMUNOTHERAPY OF PATIENTS WITH CANCER |
EP2173438A2 (en) * | 2007-07-13 | 2010-04-14 | Genentech, Inc. | Treatments and diagnostics for cancer, inflammatory disorders and autoimmune disorders |
EP2215220B1 (en) * | 2007-11-08 | 2018-01-10 | Dana-Farber Cancer Institute, Inc. | Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28 |
EP2073009A1 (en) * | 2007-12-19 | 2009-06-24 | Cell Med Research GMBH | Method for T, NK and NKT cells |
WO2009120341A2 (en) * | 2008-03-24 | 2009-10-01 | University Of South Florida | Biomarkers for predicting response to immunosuppressive therapy |
US20120088678A1 (en) * | 2010-09-08 | 2012-04-12 | Sanford-Burnham Medical Research Institute | Method for prediction of response to rheumatoid arthritis therapeutics |
CN103502438A (en) * | 2011-03-23 | 2014-01-08 | 弗雷德哈钦森癌症研究中心 | Method and compositions for cellular immunotherapy |
CA2840424C (en) * | 2011-07-01 | 2022-02-01 | Beckman Coulter, Inc. | Regulatory t cells and methods of identifying, obtaining and using to treat immuno-based disorders |
AR092423A1 (en) * | 2012-09-04 | 2015-04-22 | Univ Niigata | METHOD OF DIAGNOSIS AND TREATMENT OF CANCER DIRECTED TO MOLECULES EXPRESSED IN CANCEROSA MOTHER CELLS |
EP3552628A1 (en) | 2012-09-07 | 2019-10-16 | The Trustees Of Dartmouth College | Vista modulators for diagnosis and treatment of cancer |
WO2014140856A2 (en) | 2013-03-15 | 2014-09-18 | Graham Lord | Mir-142 and antagonists thereof for treating disease |
EP3060919A4 (en) | 2013-10-25 | 2018-02-14 | Nodality, Inc. | Methods and compositions for immunomodulation |
EP3197495A4 (en) | 2014-09-28 | 2018-08-29 | The Regents of The University of California | Modulation of stimulatory and non-stimulatory myeloid cells |
WO2016172010A1 (en) * | 2015-04-20 | 2016-10-27 | Effector Therapeutics, Inc. | Inhibitors of immune checkpoint modulators for use in treating cancer and infections |
CA2991044A1 (en) * | 2015-06-29 | 2017-01-05 | Verastem, Inc. | Therapeutic compositions, combinations, and methods of use |
EP3417293A1 (en) | 2016-02-18 | 2018-12-26 | Institut Gustave Roussy | Methods and kits for predicting the sensitivity of a subject to immunotherapy |
EP3576757B1 (en) | 2017-02-06 | 2021-06-09 | Novartis AG | Method of predicting response to immunotherapy |
SG11201907102XA (en) | 2017-02-07 | 2019-08-27 | Univ Saitama Medical | Immunological biomarker for predicting clinical effect of cancer immunotherapy |
US20200393469A1 (en) | 2017-05-16 | 2020-12-17 | Kurume University | Method for determining eligibility of brain tumor patient for tailor-made type peptide vaccine agent |
-
2018
- 2018-02-06 SG SG11201907102XA patent/SG11201907102XA/en unknown
- 2018-02-06 US US16/484,071 patent/US11293924B2/en active Active
- 2018-02-06 CN CN201880018787.0A patent/CN110446928B/en active Active
- 2018-02-06 EP EP18708226.8A patent/EP3580569B1/en active Active
- 2018-02-06 KR KR1020237001717A patent/KR102617574B1/en active IP Right Grant
- 2018-02-06 KR KR1020197024565A patent/KR102490278B1/en active IP Right Grant
- 2018-02-06 EP EP22153621.2A patent/EP4039260B1/en active Active
- 2018-02-06 JP JP2019526634A patent/JP6664684B1/en active Active
- 2018-02-06 UY UY0001037594A patent/UY37594A/en not_active Application Discontinuation
- 2018-02-06 CN CN202310639111.6A patent/CN116712458A/en active Pending
- 2018-02-06 WO PCT/JP2018/004090 patent/WO2018147291A1/en active Search and Examination
- 2018-02-06 MX MX2019009386A patent/MX2019009386A/en unknown
- 2018-02-06 AU AU2018218844A patent/AU2018218844B2/en active Active
- 2018-02-06 CA CA3052027A patent/CA3052027A1/en active Pending
- 2018-02-07 TW TW107104272A patent/TWI795386B/en active
- 2018-02-07 TW TW112104159A patent/TW202323820A/en unknown
-
2019
- 2019-08-05 IL IL268524A patent/IL268524A/en unknown
-
2020
- 2020-02-03 JP JP2020016573A patent/JP7067804B2/en active Active
-
2022
- 2022-02-25 US US17/681,616 patent/US20220178933A1/en active Pending
- 2022-04-21 JP JP2022070115A patent/JP2022105066A/en active Pending
-
2023
- 2023-06-22 US US18/339,853 patent/US20230349909A1/en active Pending
- 2023-12-25 JP JP2023218163A patent/JP2024023862A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102617574B1 (en) | 2023-12-22 |
US20230349909A1 (en) | 2023-11-02 |
JP2020512530A (en) | 2020-04-23 |
CN116712458A (en) | 2023-09-08 |
US20220178933A1 (en) | 2022-06-09 |
TW201833551A (en) | 2018-09-16 |
JP2024023862A (en) | 2024-02-21 |
IL268524A (en) | 2019-09-26 |
KR20230017355A (en) | 2023-02-03 |
JP7067804B2 (en) | 2022-05-16 |
TW202323820A (en) | 2023-06-16 |
CN110446928B (en) | 2023-06-20 |
JP2020073924A (en) | 2020-05-14 |
WO2018147291A1 (en) | 2018-08-16 |
EP4039260A1 (en) | 2022-08-10 |
US20200025768A1 (en) | 2020-01-23 |
JP6664684B1 (en) | 2020-03-13 |
MX2019009386A (en) | 2019-11-05 |
KR102490278B1 (en) | 2023-01-18 |
JP2022105066A (en) | 2022-07-12 |
AU2018218844B2 (en) | 2024-08-01 |
KR20190112027A (en) | 2019-10-02 |
AU2018218844A1 (en) | 2019-09-19 |
US11293924B2 (en) | 2022-04-05 |
EP4039260B1 (en) | 2024-04-17 |
EP3580569B1 (en) | 2022-03-09 |
CA3052027A1 (en) | 2018-08-16 |
CN110446928A (en) | 2019-11-12 |
UY37594A (en) | 2018-08-31 |
EP3580569A1 (en) | 2019-12-18 |
TWI795386B (en) | 2023-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268524A (en) | Immunological biomarker for predicting clinical effect of cancer immunotherapy | |
EP3524689A4 (en) | Method for predicting the prognosis of breast cancer patient | |
HK1246828A1 (en) | Biomarker panel for the detection of cancer | |
EP3597766A4 (en) | Novel biomarker for cancer immunotherapy | |
EP3230745A4 (en) | Plasma autoantibody biomarkers for basal like breast cancer | |
PL3455625T3 (en) | Methods for predicting the usefulness of neoantigens for immunotherapy | |
GB201607393D0 (en) | Biomarkers for early diagnosis of ovarian cancer | |
EP3201360A4 (en) | Methods for assessing risk of developing breast cancer | |
IL270717A (en) | Biomarkers for diagnosis of lung cancer | |
HK1248803A1 (en) | Specific biomarker set for non-invasive diagnosis of liver cancer | |
EP3204008A4 (en) | Use of biomarkers for predicting clinical sensitivity to cancer treatment | |
EP3743058A4 (en) | Methods for predicting tumor response to immunotherapy | |
EP2998740A4 (en) | Method for predicting clinical effect of immunotherapy | |
EP3574113A4 (en) | Improved methods for assessing risk of developing breast cancer | |
GB201619808D0 (en) | Biomarkers for the prognosis and diagnosis of cancer | |
EP3189332A4 (en) | Biomarkers for detection of breast cancer | |
PT3791186T (en) | Antigen biomarker of microsatellite instability | |
GB201617722D0 (en) | Method for determining prognosis of cancer | |
EP3060914A4 (en) | Methods of determining breast cancer prognosis | |
GB201908085D0 (en) | Methods of determining cancer | |
EP3638308A4 (en) | Biomarkers for predicting tumor response to and toxicity of immunotherapy | |
EP3440468B1 (en) | Biomarkers for predicting degree of weight loss | |
AU2017275640A1 (en) | Biomarkers for predicting degree of weight loss | |
AU2017905180A0 (en) | Biomarker of disease | |
GB201414362D0 (en) | Biomarkers for early diagnosis of ovarian cancer |